Evommune, Inc. EVMN
7.24 USD +0.36 (+5.23%)
Regular-session close
7.30 +0.06 +0.83%
After hours · Nov 19, 7:56 PM ET
6.92 Day range 7.39
5.10 52-week range 31.57
- YTD
- -57.71%
- 1 year
- -62.47%
News
benzinga.com Needham Maintains Buy on Evommune, Lowers Price Target to $25 Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.
benzinga.com Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate Evommune (NYSE:EVMN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.84) by 1.19 percent. This is a 89.47 percent increase over losses of $(8.07) per…
businesswire.com Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key…
businesswire.com Evommune to Present at Upcoming Investor Conferences PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key…
marketbeat.com Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development Evommune NYSE: EVMN has licensed global development rights outside Greater China to EVO570, an experimental oral drug for inflammatory diseases, in a deal with Hinova Pharmaceuticals that includes…
seekingalpha.com Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
businesswire.com Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key…
businesswire.com Evommune Announces $30 Million Private Placement PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key…benzinga.com Evommune Receives Exclusive License From Hinova Pharmaceuticals To Develop, Manufacture, Commercialize EVO570 Outside China; Hinova To Get $30M Upfront Payment Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302)
businesswire.com Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals PALO ALTO, Calif. & NEW YORK & CHENGDU, China--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
businesswire.com Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key…
businesswire.com Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key…
benzinga.com Evommune Halts Atopic Dermatitis Program Following Trial Failure On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic…
reuters.com Evommune scraps eczema drug after trial miss, shares plunge Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.
businesswire.com Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key…
defenseworld.net Brokerages Set Evommune, Inc. (NYSE:EVMN) PT at $43.25 Evommune, Inc. (NYSE: EVMN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are covering the company, MarketBeat.com reports. One…
businesswire.com Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key…
businesswire.com Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key…
prnewswire.com Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July…
seekingalpha.com Evommune's Healthy Balance Sheet Buys Them Time For AD Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD…
prnewswire.com Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint. NEW YORK,…
zacks.com EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.
benzinga.com Evommune's Skin Disorder Study Falls Short Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
